Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00747825 · ClinicalTrials.gov registry record · Phase 1
Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma
A Phase 1 study, sponsored by Molecular Insight Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00747825 is a Phase 1 study that was terminated before completion, run by Molecular Insight Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT00747825, a Phase 1 study, was terminated before completion, sponsored by Molecular Insight Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is an open-label, single dose study for patients 18 years of age or older with confirmed metastatic melanoma. Up to 12 patients will be enrolled and all will receive an injection of approximately 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145 administered via IV injection. The study will consist of a single dosing day followed by a 7-day assessment period and 21-day follow-up period. The total duration of the study from screening to final follow-up visit is approximately 60 days.
Interventions
- DRUG 131-I-MIP-1145
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00747825
The ClinicalTrials.gov registry entry for NCT00747825 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molecular Insight Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 131-I-MIP-1145 is the first listed.
NCT00747825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00747825 about?
NCT00747825 is a clinical study titled "Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma". This is an open-label, single dose study for patients 18 years of age or older with confirmed metastatic melanoma. Up to 12 patients will be enrolled and all will receive an injection of approximately 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145 administered via IV injection. The study will consis...
What is the current status of trial NCT00747825?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-12. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00747825?
The interventions under investigation include: 131-I-MIP-1145 (DRUG).
Who is sponsoring clinical trial NCT00747825?
This trial is sponsored by Molecular Insight Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.